Schistosomiasis is one of the most prevalent global helminth infections leading to acute and chronic disease, affecting 200 million people and threatening over 800 million in 54 endemic countries. The WHO 2021−2030 road map for neglected tropical diseases targets Schistosomiasis for elimination as a public health problem in all endemic countries and highlighting that an integrated approach in which therapeutic intervention will play an important part. Current treatment relies on a single 45 year-old drug – praziquantel, which has significant limitations as a therapeutic. With signs of resistance emerging and a vaccine still a distant prospect, discovery of novel anti Schistosoma drugs is of ultimate importance. Using a combination of computational and experimental techniques we have identified compounds that inhibit the activity of a protein shown to be crucial for the parasites survival. Our aim is to develop these promising new compounds, improving their efficacy and demonstrating their effectiveness at killing the parasite.